

NCI SBIR AND YOUR STATE:

MICHIGAN



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$23.3 million** in funding across **23 Phase II SBIR/STTR grants** to small businesses in Michigan. The following economic impact estimates quantify the program's contributions to the state's economy:

	\$65.2M	IN TOTAL DIRECT SALES
	\$417.1M	IN TOTAL ECONOMIC IMPACT
	2.1K	JOBS CREATED
	\$13.2M	IN STATE & LOCAL TAXES COLLECTED
	18	COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Michigan: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$57.6M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

DELPHINUS MEDICAL TECHNOLOGIES, INC.

Delphinus Medical Technologies, Inc. used SBIR funding to develop SoftVue™, a 3D Whole Breast Ultrasound Tomography System. FDA PMA approved in October 2021, Delphinus secured \$30 million in Series D financing for global commercialization in September 2022 and an additional \$12 million in growth capital from Trinity Capital in August 2023.

COMPENDIA BIOSCIENCE, INC.

University of Michigan startup Compendia Bioscience, Inc. used SBIR funding to develop Oncomine™, an oncology database used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. It was acquired in October 2012 by Life Technologies Corp.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.